Compare VIOT & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIOT | CYPH |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | China | United States |
| Employees | N/A | 6 |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.8M | 73.4M |
| IPO Year | 2018 | N/A |
| Metric | VIOT | CYPH |
|---|---|---|
| Price | $1.02 | $1.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 193.7K | ★ 2.6M |
| Earning Date | 03-25-2026 | 05-13-2026 |
| Dividend Yield | ★ 13.49% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.04 | N/A |
| P/E Ratio | $3.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.92 | $0.50 |
| 52 Week High | $4.33 | $3.70 |
| Indicator | VIOT | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 41.42 | 65.75 |
| Support Level | $0.92 | $0.83 |
| Resistance Level | $1.14 | $1.14 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 33.16 | 63.24 |
Viomi Technology Co Ltd, along with its subsidiaries, specializes in the development and sale of Internet-of-Things-enabled smart home products, particularly focusing on home water solutions. The company markets its products in China and generates the majority of its revenue through the sale of smart water purification systems and other connected home devices designed to improve convenience and automation in residential settings. Its product offerings include water purification products, water heaters, smart water kettles, electric kettles, water filters, range hoods, gas stoves, and other small appliances.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.